Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
44.50    -0.50 (-1.11%)
Bid:
44.00
Ask:
45.00
Spread: 1.00 (2.273%)
Market Cap: £85.38m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Corporate Update

18 Jan 2016 07:00

RNS Number : 1092M
Iofina PLC
18 January 2016
 

 

18 January 2016

Iofina plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

Corporate Update

Annualised iodine production increase of over 73%

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, today provides an update to the market regarding record crystalline iodine production totals in 2015.

 

During the period, Iofina produced a total of 569.1 metric tonnes ("MT") of crystalline iodine (2014: 327.7MT) from its IOsorb® plants. Although the Company experienced power outages at its IOsorb® plants and at its partners' operations due to adverse weather conditions in late December, resulting in a loss of anticipated production of about 5-7MT of crystalline iodine in the month, the Board is pleased with the like-for-like increase of over 73% of crystalline iodine from our IOsorb® facilities in its core area in Oklahoma.

 

As previously stated, restrictions of particular Salt Water Disposal wells ("SWD") due to seismic activity has marginally impacted the Company's total brine supply. The Company is developing alternatives to mitigate risk associated with potential future restrictions of individual SWDs. The Board's aim is to not only limit risk exposure, but increase the available brine supply to Iofina's IOsorb® plants. Iofina is working with its partners on strategic plans to reduce risk and potentially expand brine supply and the Board looks forward to updating the market in due course.

 

Under current operating conditions, Iofina expects to produce 250-270MT of crystalline iodine in H1 2016 from its five existing IOsorb® plants. This production estimated range is based on the current injection restrictions at certain sites. Again, the Company is working closely with its partners to mitigate and possibly eliminate these flow restrictions.

 

Iofina continues to consume a large amount of its produced iodine through its halogen derivatives division, Iofina Chemical ("IC"). Iodine use at IC was at record levels for the Company in 2015. The Company is encouraged to report that it has successfully marketed and sold significant quantities of IOsorb® produced iodine into the global market place. In line with other commodities in the global market, the price for iodine has continued to soften. Iodine worldwide is generally sold in US Dollars. The strengthening of the US Dollar versus other global currencies has further impacted iodine pricing.

 

In order to manage the impact of these extraneous fluctuations, the Company has successfully cut expenses, reduced production and corporate costs and continues to investigate additional cost cutting measures. These measures are expected to protect the Company's cash position and have a positive impact on the Company's gross margins for the current financial year as it moves toward cashflow positive operations.

 

 

 

 

Commenting, President and CEO Dr. Tom Becker, stated: 

 

"While the Board is encouraged by the sizeable year-on-year iodine production increase and overall operational gains, with the backdrop of an uncertain capital markets and commodity climate, 2016 will be a year of prudency and value protection. The Company remains focused on seeking out ways to streamline efficiencies and mitigate risk, while expanding production at its current plants and future operations." 

 

 

For further information, please contact:

 

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Joanna Scott

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Dominic Barretto/Harriet Jackson

Yellow Jersey PR Limited

Tel: +44 (0)7768 537 739

About Iofina:

Iofina specializes in the exploration and production of iodine, iodine specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Montana, Kentucky and Oklahoma. It has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end-products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilizes its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

www.iofina.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBIGDBCGBBGLR
Date   Source Headline
23rd Sep 20214:35 pmRNSPrice Monitoring Extension
22nd Sep 20219:58 amRNSHolding(s) in Company
10th Sep 20214:15 pmRNSHolding(s) in Company
10th Sep 20213:25 pmRNSHolding(s) in Company
15th Jul 20217:00 amRNSH1 2021 Update
18th Jun 20214:36 pmRNSPrice Monitoring Extension
18th Jun 20213:20 pmRNSResult of AGM
27th May 20214:40 pmRNSSecond Price Monitoring Extn
27th May 20214:36 pmRNSPrice Monitoring Extension
27th May 20212:06 pmRNSSecond Price Monitoring Extn
27th May 20212:00 pmRNSPrice Monitoring Extension
27th May 202111:06 amRNSSecond Price Monitoring Extn
27th May 202111:00 amRNSPrice Monitoring Extension
27th May 20217:00 amRNSHolding(s) in Company
25th May 20217:00 amRNSAnnual Financial Report
21st May 20215:50 pmRNSNotice of Results
15th Apr 20217:00 amRNSQ1 2021 Update
1st Mar 20215:36 pmRNSDirector/PDMR Shareholding
24th Feb 20217:00 amRNSDirector/PDMR Shareholding
19th Feb 20217:00 amRNSDirector/PDMR Shareholding
19th Jan 20217:00 amRNSMarket Update
22nd Dec 20204:41 pmRNSSecond Price Monitoring Extn
22nd Dec 20204:35 pmRNSPrice Monitoring Extension
22nd Dec 20202:05 pmRNSSecond Price Monitoring Extn
22nd Dec 20202:00 pmRNSPrice Monitoring Extension
16th Dec 202011:50 amRNSGrant of Share Options
16th Oct 20207:00 amRNSQ3 2020 Update
13th Oct 20204:40 pmRNSSecond Price Monitoring Extn
13th Oct 20204:35 pmRNSPrice Monitoring Extension
29th Sep 20207:00 amRNSINTERIM RESULTS
23rd Sep 20207:09 amRNSPrice Monitoring Extension
23rd Sep 20207:07 amRNSSecond Price Monitoring Extn
23rd Sep 20207:04 amRNSPrice Monitoring Extension
23rd Sep 20207:01 amRNSSecond Price Monitoring Extn
22nd Sep 20204:41 pmRNSSecond Price Monitoring Extn
22nd Sep 20204:36 pmRNSPrice Monitoring Extension
22nd Sep 20202:05 pmRNSSecond Price Monitoring Extn
22nd Sep 20202:00 pmRNSPrice Monitoring Extension
22nd Sep 20207:00 amRNSDebt Refinancing Signed
26th Aug 20207:00 amRNSDebt Update
31st Jul 20208:00 amRNSLaunch of new website
22nd Jul 202011:06 amRNSSecond Price Monitoring Extn
22nd Jul 202011:00 amRNSPrice Monitoring Extension
22nd Jul 20207:00 amRNSCorporate Update
30th Jun 20202:36 pmRNSDebt Update
30th Jun 202011:52 amRNSResult of AGM
26th Jun 20201:26 pmRNSChange of venue for AGM on 30 June 2020
26th Jun 20207:00 amRNSIO#8 and Debt Update
27th May 20207:00 amRNSFinal Results
19th May 20204:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.